👉 Most biotech founders think fundraising stalls because investors do not fully understand the science. In reality, biotech fundraising rarely fails on science alone . It fails when investors sense hesitation behind decisions, blurred priorities between milestones, or leadership teams that cannot clearly articulate what matters most right now. 👉 These signals appear in the first conversations, long before a term sheet is discussed. Fundraising is not a performance. It is a

👉 In biotech, it is widely assumed that strong data naturally leads to strong execution . If experiments are rigorous and results are validated, progress should be inevitable. This belief is deeply embedded in scientific culture, and it feels rational. Yet in reality, biotech execution rarely breaks because of weak data . It breaks because teams avoid making hard choices. More precisely, they avoid explicitly acknowledging the tradeoffs that shape every execution path . 👉 F